CD40LG and Autoimmunity: Recently, a collaborative work by Viela Bio, AstraZeneca, and MedImmune demonstrated that novel CD40L-targeting non-antibody scaffold protein did not induce platelet aggregation in vitro and improved disease activity of patients with autoimmunity without any complications [43].